Novavax stock jumps after submission of data on COVID-19 vaccine candidate to Health Canada, EMA completed

Shares of Novavax Inc. NVAX, +6.56% shot up 6.8% in premarket trading Monday, after the biotechnology company said it has completed its rolling submission to Canada's health authorities, Health Canada, for the authorization of its COVID-19 vaccine candidate. The company said it has also completed the submission of all data to the European Medicines Agency (EMA) for regulatory review.